Kalvista pharmaceuticals, inc. (KALV)
Income statement / Yearly
Apr'19Apr'18Apr'17Apr'16Dec'15Apr'15Dec'14Dec'13
Revenue

16,127

8,394

1,504

-

-

-

-

-

Revenue

-

-

-

2,133

-

-

-

-

Grant income

-

-

-

-

-

1,804

-

-

License Revenue

-

-

-

-

29

-

29

415

Operating expenses:
Research and development

35,021

18,237

12,666

14,661

16,199

8,285

8,294

4,229

General and administrative

10,926

8,862

11,177

2,653

4,866

1,608

3,412

1,402

Total operating expenses

45,947

27,099

23,843

17,314

21,065

9,893

11,706

5,631

Operating loss

-29,820

-18,705

-22,339

-15,181

-21,036

-8,089

-11,677

-5,216

Other income:
Interest income

1,397

82

36

50

5

19

2

2

Foreign currency exchange gain

49

-1,574

1,371

1,661

-

-

-

-

Interest expense

-

-

-

-

1,188

-

1,082

405

Loss on extinguishment of convertible promissory notes

-

-

-

-

-3,177

-

-

-

Other income

7,682

4,392

2,329

2,034

550

844

-602

-59

Total other income

9,128

2,900

3,736

3,745

-3,810

863

-1,682

-462

Loss before income taxes

-20,692

-15,805

-18,603

-

-

-

-

-

Income tax expense

124

-

-

-

-

-

-

-

Net loss

-20,816

-15,805

-18,603

-11,436

-24,846

-7,226

-13,359

-5,678

Other comprehensive income (loss):
Foreign currency translation adjustments

-1,257

1,534

-2,568

-2,240

-

-156

-

-

Unrealized holding gains on available-for-sale securities

440

-

-

-

-

-

-

-

Comprehensive loss

-21,633

-14,271

-21,171

-13,676

-

-7,382

-

-

Net loss per share to common stockholders, basic and diluted

-1.38

-1.53

-4.47

-26.17

-1.30

-34.94

-21.81

-13.42

Weighted average common shares outstanding, basic and diluted

15,080

10,321

4,646

591

19,082

263

612

423